Syncona investments

Investing into best-in-class therapeutics companies

Syncona has £55.0 million of value in its investments, typically where we do not hold Board seats or manage the investment actively alongside executive teams. Our assets held within our investments are CRT Pioneer Fund, Forcefield Therapeutics, Biomodal (formerly Cambridge Epigenetix), and Adaptimmune.


Key facts

Unless stated all financials at 31 December 2023


Value in its investments




Our largest investment in 2023

Assets held within our investments